PURSUANT TO 5
CFR 1320.14(i), A ONE YEAR APPROVAL HAS BEEN GRANTED THROUGH MAY
1986 IN ORDER TO EVALUATE THE REVISED NEW DRUG APPROVAL PROCESS. IN
ADDITION, GIVEN THE APPARENT PUBLIC CONFUSION OVER THE REPORTING
REQUIREMENTS IN SECTION 314.50(f) FDA WILL PROVIDE INFORMATI TO
INTERESTED INDIVIDUALS TO CLARIFY THE REQUIREMENTS OF THIS
SECTION.
Inventory as of this Action
Requested
Previously Approved
05/31/1986
05/31/1986
09/30/1985
655
0
20
1,499,266
0
6,400
0
0
0
THE REGULATIONS ESTABLISH A REGULATORY
SCHEME UNDER WHICH DRUG MANUFACTURERS CAN SUBMIT DATA AND
INFORMATION ON THE SAFETY AND EFFECTIVENESS OF NEW DRUGS AND
ANTIBIOTICS TO OBTAIN FEDERAL APPROVAL MARKET THEM AND FDA CAN
MONITOR THE QUALITY OF THE NATION'S DRUG SUPPLY.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.